Project Summary/Abstract
Multiple studies have demonstrated that Natural Killer (NK) cell activity, including antibody dependent cellular
cytotoxicity (ADCC), is correlated with delayed HIV disease progression. Furthermore, protein engineering has
revealed that glycosylation of the antibody Fc region, particularly for IgG1, affects Fc gamma receptor IIIa (CD16)
binding affinity and ADCC activity. However, the mechanism by which Fc glycosylation alters ADCC activity
remains incompletely understood, specifically regarding the spatiotemporal localization of CD16 and associated
signaling molecules. The long-term goal of this proposal is to obtain a more complete understanding of how
antibody glycobiology interplays with the innate immune response to generate guiding principles for more
effective vaccines and therapeutics. The objective of this proposal is to determine how antibody glycosylation
influences CD16 mediated NK cell activation at single cell resolution in HIV infected individuals and to define the
spaciotemporal dynamics of CD16-based signaling. The rationale for this work is that the combination of cutting-
edge microscopy observations and temporal protein analysis will provide new insights into ADCC function with
immediate impacts on antibody therapeutic design. Our central hypothesis is that specific antibody glycosylation
profiles will differentially modulate CD16 interactions and ADCC activity through changes in CD16 signaling. Our
central hypothesis will be tested in two specific aims: 1) Determine how narrow glycosylation profiles of
monoclonal antibodies (mAbs) directed to key sites of vulnerability on the HIV Envelope (Env) affect
phosphorylation states of signaling proteins during NK cell ADCC, comparing NK cells from healthy and HIV+
donors; 2) Determine how antibody glycosylation alters the subcellular localization of CD16 and signaling
proteins within the NK cell immunological synapse (NKIS) throughout each stage of ADCC. We will pursue these
aims with innovative techniques in multi-color quantitative fluorescent microscopy and spectral flow cytometry.
Detailed single cell studies using MINFLUX nanoscopy, a super-resolution fluorescent microscopy technique
capable of 2 nm or better spatial resolution in 3D, will complement our proteomic analysis. The expected outcome
of our studies is that marrying our quantitative proteomic analysis with more detailed mechanistic studies of
ADCC will rationalize previously observed changes in cellular activity associated with differential antibody
glycosylation. Our results will impact human health by providing a molecular rational for the effect of antibody
glycosylation on ADCC activity, thus improving antibody and cellular therapeutic development for HIV as well as
a broad range of other diseases.